Skip to content
DraconiticResearch
Search Sources API
201,818 studies31 sourcesUpdated 26 min ago
Peer-reviewedCC BY 4.0Journal of Clinical Medicine

Left Ventricular Wall Thickness in Hypertrophic Cardiomyopathy and Cardiac Amyloidosis: A Multimodality Imaging Comparison

  • Zubair Bashir1
  • Syed Bukhari2
  • Michelle Yang1
  • Huda Jamil3
  • Mohamed Bilal Abdallah4
  • Esosa G. Odigie-Okon1
  • Wissam Khalife1
4 affiliations
  1. 1Department of Cardiology, University of Texas Medical Branch, Galveston, TX 77755, USA
  2. 2Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
  3. 3Allama Iqbal Medical College, Lahore 54700, Pakistan
  4. 4Department of Health and Human Performance, University of Houston, Houston, TX 77204, USA
Read full textPDFDOICite

Abstract

Hypertrophic cardiomyopathy (HCM) and cardiac amyloidosis (CA) are key differential diagnoses in patients presenting with an increase in left ventricular wall thickness. Despite advances in multimodal imaging, both conditions remain underrecognized due to overlapping morphological and clinical features that complicate diagnosis and treatment. However, their distinct pathophysiological mechanisms—myocardial hypertrophy and myofibrillar disarray in HCM versus extracellular deposition of misfolded amyloid protein in CA—have direct implications for management. Timely and accurate diagnosis is critical to optimizing patient care and preventing serious adverse outcomes, including sudden cardiac death. Epidemiological factors such as age, sex, and geographic distribution, along with specific clinical characteristics, can increase pretest probability and guide targeted diagnostic evaluation. As we enter a new era of precision medicine, this review comprehensively discusses the epidemiological, clinical, and imaging distinctions between HCM and CA to enhance diagnostic accuracy and clinician awareness to provide optimal care delivery.

Related

  1. Multimodality Imaging in Hypertrophic Cardiomyopathy: From Phenotyping to Precision Clinical Management.
    Niya Mileva, Panayot Panayotov
    Diagnostics (Basel, Switzerland)Peer-reviewedCC BYFull textCardiovascular medicineEurope PMC
  2. Transatrial air-assisted epicardial ventricular tachycardia ablation for hypertrophic cardiomyopathy and management of postprocedural right atrial thrombus.
    İbrahim Etem Dural, Mehmet Özgeyik, Ramazan Anıl Eşki +1
    HeartRhythm case reportsPeer-reviewedCC BY-NC-NDFull textCardiovascular medicineEurope PMC
  3. Atrial and ventricular mechanical dysfunction and myocardial injury predict long-term outcomes in hypertrophic cardiomyopathy: a retrospective cohort study
    Sheng-Liang Liu, Xue-Dong Wang, Ye Li +7
    Quantitative imaging in medicine and surgeryPeer-reviewedCC BY-NC-NDFull textMedical imaging & radiologyEurope PMC
  4. Unmasking Latent Left Ventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy
    Hyunseok Cho, Jihoon Kim, Sang-Chol Lee +2
    JACC Case ReportsPeer-reviewedCC BY-NC-ND 4.0Full textCardiovascular medicinePMCDOAJ
  5. Left Ventricular Structural, Physiological, and Transcriptomic Abnormalities in a Novel Porcine Hypertrophic Cardiomyopathy Model.
    Eric M Green, Carlos Del Rio, Kamel Shibbani +18
    JACC. Basic to translational sciencePeer-reviewedCC BY-NC-NDFull text1 citedCardiovascular medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{bashir2026left,
  title = {{Left Ventricular Wall Thickness in Hypertrophic Cardiomyopathy and Cardiac Amyloidosis: A Multimodality Imaging Comparison}},
  author = {Zubair Bashir and Syed Bukhari and Michelle Yang and Huda Jamil and Mohamed Bilal Abdallah and Esosa G. Odigie-Okon and Wissam Khalife},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  month = oct,
  doi = {10.3390/jcm15208083},
  url = {https://www.mdpi.com/2077-0383/15/20/8083},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Left Ventricular Wall Thickness in Hypertrophic Cardiomyopathy and Cardiac Amyloidosis: A Multimodality Imaging Comparison
AU  - Zubair Bashir
AU  - Syed Bukhari
AU  - Michelle Yang
AU  - Huda Jamil
AU  - Mohamed Bilal Abdallah
AU  - Esosa G. Odigie-Okon
AU  - Wissam Khalife
PY  - 2026
DA  - 2026/10/01
JO  - Journal of Clinical Medicine
DO  - 10.3390/jcm15208083
UR  - https://www.mdpi.com/2077-0383/15/20/8083
AB  - Hypertrophic cardiomyopathy (HCM) and cardiac amyloidosis (CA) are key differential diagnoses in patients presenting with an increase in left ventricular wall thickness. Despite advances in multimodal imaging, both conditions remain underrecognized due to overlapping morphological and clinical features that complicate diagnosis and treatment. However, their distinct pathophysiological mechanisms—myocardial hypertrophy and myofibrillar disarray in HCM versus extracellular deposition of misfolded amyloid protein in CA—have direct implications for management. Timely and accurate diagnosis is critical to optimizing patient care and preventing serious adverse outcomes, including sudden cardiac death. Epidemiological factors such as age, sex, and geographic distribution, along with specific clinical characteristics, can increase pretest probability and guide targeted diagnostic evaluation. As we enter a new era of precision medicine, this review comprehensively discusses the epidemiological, clinical, and imaging distinctions between HCM and CA to enhance diagnostic accuracy and clinician awareness to provide optimal care delivery.
SN  - 2077-0383
ER  -